Forecast & Rating3 analysts currently cover Kezar Life Sciences, of which 0 give a positive rating. The average price target is $6.00, about 17.7% downside from the current price of $7.29. Coverage is limited, so the data is for reference only. Data as of May 11, 2026; this does not constitute investment advice.
Apr 26, 2026Price forecast
$6.00-17.70%
Forecast & RatingHold
3analysts
- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
Target price forecast
Forecast dateMay 4, 2026
Forecast met2.1%
Stock price$7.29
Avg. target$6.0
High target$7
Low target$5
Analyst ratings
Strong buy
Buy
Hold
Sell
Strong sell
Source: S&P Global
This information is for reference only and is not investment advice.